Sholl LM, Aisner DL, Varella-Garcia M, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The lung cancer mutation consortium experience. J Thorac Oncol, 2015, 10(5): 768-777. doi:...
2. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. doi:10.1038/nature05945 3. McKeage MJ, Tin Tin S, Khwaounjoo P,...
The present study investigated the rates of detection and the positive rates of computed tomography (CT)-guided aspiration of lung biopsy for epidermal growth factor receptor (EGFR) gene and anaplastic lymphoma kinase (ALK) gene, and analyzed the relationship between gene mutation and clinical charact...
3、Liang H, Song X, Zhang Y, et al. Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study[J]. Thoracic Cancer, 2019, 10(7): 1521-1532. 4、Shim...
Li Y ,et al.,Responses tocrizotiniband chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature. Mol Clin Oncol. 2017 Aug;7(2):173-182
Objective: To investigate the mutations of EGFR gene and ALK fusion gene in lung squamous cell carcinoma. Methods: The ARMS method was used to detect the tissues in 218 patients of lung squamous cell carcinoma with paraffin tissue EGFR gene mutation and ALK fusion gene. Results: The total muta...
GENETIC mutationCYTOLOGYSPUTUMNON-small-cell lung carcinomaThe detection of driver gene mutations has become essential for lung cancer; however, insufficient sample sizes make gene panel tests difficult to use. We previously reported that the lung cancer compact panel TM (LCCP) could detect EGFR and...
This testing detects the presence of ALK gene rearrangements in tumor tissue. The test is typically ordered along with or as a follow-up test to EGFR and ROS1. If a non-small cell lung cancer has an EGFR mutation, then the affected person is likely to respond to an anti-EGFR drug ...
5. Qiu T, Li W, Zhang F, Wang B and Ying J. Major challenges in accurate mutation detection of multifocal lung adenocarcinoma by next-generation sequencing. Cancer Biol Ther. 2020; 21: 170-177. 6. Qiu T, Zhang F, Li W, Guo L and Ying J. Concurrent Presence of ALK Rearrangement an...
Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung cancers; yet the durability of response is limited by drug resistance.